Citations

Clear

3314 citation(s) found for "Yu, Alexander".

Haemodynamic determinants of improved aerobic capacity after tricuspid valve surgery in Ebstein anomaly
Egbe, Alexander C. , Miranda, William R. , Connolly, Heidi M. , Egbe, Alexander C , Miranda, William, Connolly, Heidi, Dearani, Joseph, Dearani, Joseph A.

Mayo Clinic

Heart | October 29, 2020 | Volume: 107 | Issue: 14 | Pages: 1138-1144

10.1136/heartjnl-2020-317756 | PMID 33122300 Get It

Background Although tricuspid valve surgery improves functional capacity in patients with Ebstein anomaly, it is not always associated with improvement in aerobic capacity. The purpose of this study was to identify the determinants of improved aerobic capacity after tricuspid valve surgery in adults with Ebstein anomaly with severe tricuspid regurgitation. Methods Retrospective study of patients with severe tricuspid regurgitation due to Ebstein anomaly that had tricuspid valve surgery at Mayo Clinic Rochester (2000–2019) and had preoperative and postoperative cardiopulmonary exercise tests and echocardiograms. The patients were divided into aerobic capacity(+) and aerobic capacity(-) groups depending on whether they had postoperative improvement in %-predicted peak oxygen consumption (VO2). Results Of 76 patients with severe tricuspid regurgitation due to Ebstein anomaly, 28 (37%) and 48 (63%) were in aerobic capacity(+) and aerobic capacity(-) groups, respectively. The average improvement in peak VO2 was 2.1±1.4 mL/kg/min and −0.9±0.4 mL/kg/min in the in aerobic capacity(+) and aerobic capacity(-) groups, respectively. Although both groups had similar severity of residual tricuspid regurgitation, the aerobic capacity(+) group had more postoperative improvement in right atrial (RA) function, left atrial (LA) function and left ventricular preload and stroke volume. Of the preoperative variables analysed, RA reservoir strain (relative risk 1.12; 95% CI 1.06 to 1.18); LA reservoir strain (relative risk 1.09; 95% CI 1.04 to 1.14) and LV stroke volume index (OR 1.04; 95% CI 1.01 to 1.07) were predictors of postoperative improvement in peak VO2. Conclusions One-third of patients with severe tricuspid regurgitation due to Ebstein anomaly had postoperative improvement in aerobic capacity, and atrial function indices were the best predictors of postoperative improvement in aerobic capacity. These data provide new insight into the haemodynamic determinants of exercise capacity and lay the foundation for further studies to determine whether postoperative improvement in aerobic capacity translates to improved long-term survival, and whether timing of tricuspid valve surgery based on these echocardiographic indices will improve long-term outcomes.
Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea
Ruddy, Kathryn J. , Schaid, Daniel J. , Batzler, Anthony , Cecchini, Reena S. , Trabuco, Emanuel C. , Ginsburg, Elizabeth S. , Fasching, Peter A. , Vachon, Celine M. , Ganz, Patricia A. , Norman, Aaron, Trabuco, Emanuel, Vachon, Celine, Partridge, Ann H. , Norman, Aaron D. , Fehrenbacher, Louis , Stewart, Elizabeth A. , Couch, Fergus J. , Vachon, Celine M.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | October 29, 2020 | Volume: 113 | Issue: 8 | Pages: 1105-1108

10.1093/jnci/djaa160 | PMID 33159444 Get It

Abstract Antimullerian hormone (AMH) is a promising biomarker for ovarian reserve. In this study, we assessed AMH before and 1 year after initiation of adjuvant chemotherapy on National Surgical Adjuvant Breast and Bowel Project (NSABP)/NRG Oncology B-47 in female participants aged 42 years and younger (median age = 39 years). At baseline, median AMH was 1.2 ng/mL; 13 (4.7%) values were less than 0.1 ng/mL (the threshold for detectable levels, in the perimenopause and menopause range), and 57 values (20.6%) were less than 0.5 ng/mL. At 1 year, 215 (77.6%) were less than 0.1 ng/mL, and 264 (95.3%) were less than 0.5 ng/mL. Postchemotherapy menses were reported by 46.2% of participants. Multivariable logistic regression found that the odds of having postchemotherapy menses increased with younger age, higher body mass index, and higher prechemotherapy AMH, but not by trastuzumab administration or by the choice of chemotherapy (doxorubicin-cyclophosphamide followed by paclitaxel vs docetaxel-cyclophosphamide). We conclude that higher prechemotherapy AMH predicts a lower risk of chemotherapy-induced amenorrhea and that AMH 1 year after chemotherapy initiation is not informative in this setting because it is likely to be very low.
Performance of PROMIS Physical Function, Pain Interference, and Depression Computer Adaptive Tests Instruments in Patients Undergoing Meniscal Surgery
Nwachukwu, Benedict U. , Patel, Bhavik H. , Okoroha, Kelechi R. , Verma, Nikhil N. , Cole, Brian J. , Forsythe, Brian , Forsythe, Brian , Lu, Yining , Beletsky, Alexander

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | October 24, 2020 | Volume: 2 | Issue: 5 | Pages: No page available

10.1016/j.asmr.2020.04.012 | PMID 33134980 Get It

Purpose To compare the performance of the Patient‐Reported Outcomes Measurement Information System (PROMIS) physical function (PF), pain interference (PIF), and depression computer adaptive tests (CAT) relative to legacy instruments in patients undergoing meniscal surgery. Methods Patients scheduled to undergo meniscal surgery completed legacy knee function PROMs (International Knee Documentation Committee [IKDC], Knee Injury and Osteoarthritis Outcome Score [KOOS] subscores), Marx Activity Rating Scale (MARS), Veterans‐Rand 12 (VR12), Short Form 12 (SF12), and the Brief Resilience Scale (BRS) alongside PROMIS PF, PIF, and Depression preoperatively. Spearman rank correlations were calculated, and score distributions were examined for floor and ceiling effects. Results 152 patients (46.6 ± 14.9 years, 67.1% male) completed PROMs for appropriate inclusion. PROMIS PF yielded high‐moderate to high correlations with the IKDC and KOOS subscales ( r = 0.61 to 0.73), demonstrating similar performance to the IKDC. PROMIS PIF demonstrated moderately high‐moderate to high correlations with the IKDC, KOOS subscales, VR‐12 Physical Component Score (PCS), and SF12 PCS ( r = 0.62 to 0.71), performing comparably to KOOS Pain ( r = 0.55 to 0.92). PROMIS Depression demonstrated moderate to high‐moderate correlations with the mental health legacies ( r = 0.46 to 0.66). Significant ceiling effects were observed for MARS (n = 29, 18.8%), and significant floor effects were exhibited by PROMIS Depression (n = 38, 25%) and MARS (n = 27, 17.6%). Conclusion The PROMIS PF, PIF CAT, and Depression instruments exhibit comparable performance profiles relative to legacy knee PROMs. PROMIS PF and PIF demonstrated no floor and ceiling effects, whereas PROMIS Depression exhibited a significant relative floor effect. PROMIS PF and PIF may be appropriately used to establish functional baselines preoperatively. Level of Evidence IV, diagnostic case series.
Development of novel methods for non-canonical myeloma protein analysis with an innovative adaptation of immunofixation electrophoresis, native top-down mass spectrometry, and middle-down de novo sequencing
Deighan, W. Ian, Winton, Valerie J. , Melani, Rafael D. , Anderson, Lissa C. , McGee, John P. , Schachner, Luis F. , Barnidge, David R. , Murray, David , Alexander, H. Denis, Gibson, David S. , Deery, Michael J. , McNicholl, Feargal, McLaughlin, Joseph , Kelleher, Neil L. , Thomas, Paul M. , Barnidge, David, Kelleher, Neil L

Mayo Clinic

Clinical Chemistry and Laboratory Medicine (CCLM) | October 24, 2020 | Volume: 59 | Issue: 4 | Pages: 653-661

10.1515/cclm-2020-1072 | PMID 33079696 Get It

Abstract Objectives Multiple myeloma (MM) is a malignant plasma cell neoplasm, requiring the integration of clinical examination, laboratory and radiological investigations for diagnosis. Detection and isotypic identification of the monoclonal protein(s) and measurement of other relevant biomarkers in serum and urine are pivotal analyses. However, occasionally this approach fails to characterize complex protein signatures. Here we describe the development and application of next generation mass spectrometry (MS) techniques, and a novel adaptation of immunofixation, to interrogate non-canonical monoclonal immunoproteins. Methods Immunoprecipitation immunofixation (IP-IFE) was performed on a Sebia Hydrasys Scan2. Middle-down de novo sequencing and native MS were performed with multiple instruments (21T FT-ICR, Q Exactive HF, Orbitrap Fusion Lumos, and Orbitrap Eclipse). Post-acquisition data analysis was performed using Xcalibur Qual Browser, ProSight Lite, and TDValidator. Results We adapted a novel variation of immunofixation electrophoresis (IFE) with an antibody-specific immunosubtraction step, providing insight into the clonal signature of gamma-zone monoclonal immunoglobulin (M-protein) species. We developed and applied advanced mass spectrometric techniques such as middle-down de novo sequencing to attain in-depth characterization of the primary sequence of an M-protein. Quaternary structures of M-proteins were elucidated by native MS, revealing a previously unprecedented non-covalently associated hetero-tetrameric immunoglobulin. Conclusions Next generation proteomic solutions offer great potential for characterizing complex protein structures and may eventually replace current electrophoretic approaches for the identification and quantification of M-proteins. They can also contribute to greater understanding of MM pathogenesis, enabling classification of patients into new subtypes, improved risk stratification and the potential to inform decisions on future personalized treatment modalities.
S2958 Endometriomas as the Cause of Abdominal Wall Masses in a Woman With Cyclical Abdominal Pain
Alexander, Glenn L., Urquhart, Siri A.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S1555-S1556

10.14309/01.ajg.0000713880.92900.ca Get It

Comparison of reconstructive techniques following oncologic intraarticular resection of proximal humerus
Houdek, Matthew T. , Bukowski, Brandon R., Athey, Alexander G., Elhassan, Bassem T. , Rose, Peter S. , Barlow, Jonathan D. , Sanchez-Sotelo, Joaquin, Houdek, Matthew T , Morrey, Mark E. , Wagner, Eric R. , Sánchez‐Sotelo, Joaquín

Mayo Clinic

Journal of Surgical Oncology | October 23, 2020 | Volume: 123 | Issue: 1 | Pages: 133-140

10.1002/jso.26271 | PMID 33095924 Get It

AbstractIntroductionThe proximal humerus is a common site of primary and metastatic disease in the upper extremity. Historically, the goal of a hemiarthroplasty reconstruction was to provide a stable platform for hand and elbow function, with limited shoulder function. Techniques utilizing a reverse endoprosthesis (endoprosthetic replacement [EPR]) and allograft‐prosthetic composite (APC) have been developed; however, there is a paucity of comparative studies.MethodsA total of 83 (42 females, 41 males) patients undergoing an intraarticular resection of the humerus were reviewed. Reconstructions included 30 reverse and 53 hemiarthroplasty; including hemiarthroplasty EPR (n = 36) and APC (n = 17), and reverse EPR (n = 20) and APC (n = 10).ResultsReverse reconstructions had improved forward elevation (85° vs. 44°, p < .001) and external rotation (30° vs. 21°; p < .001) versus a hemiarthroplasty. Reverse reconstructions had improved American Shoulder and Elbow Surgeons scores (65 vs. 57; p = .01) and Musculoskeletal Tumor Society 93 scores (72 vs. 63; p < .001) versus hemiarthroplasty. Subluxation of the reconstruction was a common (n = 23, 27%), only occurring in hemiarthroplasty patients (EPR [n = 13, 36%] and APC [n = 10, 59%]).ConclusionThe current series highlights the improved functional outcome in patients undergoing reconstruction with a reverse arthroplasty compared to the traditional hemiarthroplasty. Currently reverse shoulder arthroplasty (APC or EPR) is our preferred methods of reconstruction in this patient population.
Stable interval bone density in patients with eosinophilic oesophagitis on topical steroids
Schupack, Daniel , Sami, Sarmed S. , Geno, Debra M., Lavey, Crystal, Katzka, David A. , Alexander, Jeffrey A. , Otaki, Fouad , Clarke, B.L. , Ravi, Karthik

Mayo Clinic

GastroHep | October 23, 2020 | Volume: 2 | Issue: 6 | Pages: 272-280

10.1002/ygh2.431 Get It

In Vivo Assessment of Glutamine Anaplerosis into the TCA Cycle in Human Pre-malignant and Malignant Clonal Plasma Cells
Gonsalves, Wilson I. , Jang, Jin Sung , Jessen, Erik , Hitosugi, Taro , Evans, Laura , Petterson, Xuan-Mai, Bush, Alexander Graham, Gransee, Jaimee, Anderson, Emilie I., Kumar, Shaji , Sreekumaran, K., Gonsalves, Wilson , Evans, Laura, Jevremović, Dragan

Mayo Clinic

No container title available | October 22, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-93939/v1 Get It

Abstract BackgroundOverexpression of c-Myc is required for the progression of pre-malignant plasma cells in monoclonal gammopathy of undetermined significance (MGUS) to malignant plasma cells in multiple myeloma (MM). c-Myc also increases glutamine anaplerosis into the tricarboxylic acid (TCA) cycle within cancer cells. Whether increased glutamine anaplerosis is associated with the progression of pre-malignant to malignant plasma cells is unknown.MethodsHuman volunteers (N = 7) and patients with MGUS (N = 11) and MM (N = 12) were prospectively recruited to undergo an intravenous infusion of 13C-labelled glutamine followed by a bone marrow aspiration to obtain bone marrow cells and plasma.ResultsDespite notable heterogeneity, stable isotope resolved metabolomics (SIRM) revealed that the mean 13C-labelled glutamine anaplerosis into the TCA cycle was higher in malignant compared to pre-malignant bone marrow plasma cells relative to the remainder of their paired bone marrow mononuclear cells. RNA sequencing demonstrated a higher relative mRNA expression of c-Myc and glutamine transporters such as ASCT2 and SN2 in malignant compared to pre-malignant bone marrow plasma cells. Finally, higher quantitative levels of TCA cycle intermediates in the bone marrow plasma differentiated MM from MGUS patients.ConclusionMeasurement of the in vivo activity of glutamine anaplerosis into the TCA cycle provides novel insight into the metabolic changes associated with the transformation of pre-malignant plasma cells in MGUS to malignant plasma cells in MM.
8q24 Clear Cell Renal Cell Carcinoma Germline Variant is Associated with VHL Mutation Status and Clinical Aggressiveness
Eckel‐Passow, Jeanette E. , Yan, Huihuang , Kosel, Matthew, Serie, Daniel, Decker, Paul A. , Jenkins, Robert B. , Costello, Brian A. , Leibovich, Bradley C. , Parker, Alexander S. , Decker, Paul A. , Ho, Thai H.

Mayo Clinic

No container title available | October 22, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-48012/v3 Get It

Abstract Background: The four most commonly-mutated genes in clear cell renal cell carcinoma (ccRCC) tumors are BAP1, PBRM1, SETD2 and VHL. And, there are currently 14 known RCC germline variants that have been reproducibly shown to be associated with RCC risk. However, the association of germline genetics with tumor genetics and clinical aggressiveness are unknown.Methods: We analyzed 420 ccRCC patients from The Cancer Genome Atlas (TCGA). Molecular subtype was determined based on acquired mutations in BAP1, PBRM1, SETD2 and VHL. Aggressive subtype was defined clinically using Mayo SSIGN score and molecularly using the ccA/ccB gene expression subtype. Publically-available Hi-C data were used to link germline risk variants with candidate target genes. Results: The 8q24 variant rs35252396 was significantly associated with VHL mutation status (OR=1.6, p=0.0037) and SSIGN score (OR=1.9, p=0.00094), after adjusting for multiple comparisons. We observed that, while some germline variants have interactions with nearby genes, some variants demonstrate long-range interactions with target genes.Conclusions: These data further demonstrate the link between rs35252396, HIF pathway and ccRCC clinical aggressiveness, providing a more comprehensive picture of how germline genetics and tumor genetics interact with respect to tumor development and progression.
Outcomes of Surgical Management of Intraosseous Ganglia of the Carpal Bones: A Case Series
Zelenski, Nicole A. , Corona, Jacqueline, Shin, Alexander Y. , Shin, Alexander Y , Bishop, Allen T.

Mayo Clinic

HAND | October 21, 2020 | Volume: 17 | Issue: 5 | Pages: 893-898

10.1177/1558944720963873 | PMID 33084381 Get It

Background Intraosseous ganglia of the carpal bones are uncommon with sparse publications to guide treatment. The purpose of this study was to review a single-institution experience to determine the outcomes of patients with surgically treated intraosseous carpal ganglia. Methods Skeletally mature patients with intraosseous carpal ganglia between 1995 and 2016 treated operatively were identified. Demographic information, clinical data, and radiographic studies were evaluated. Results Thirty-three ganglia in 31 patients were identified. Intraosseous ganglia were located in the lunate (23), scaphoid (9), and trapezoid (1). Patients who presented with pathologic fracture or collapse had larger intraosseus ganglia than those presenting with pain alone. Surgery significantly improved pain. Patients treated with debridement with autograft bone graft had a higher consolidation rate compared with allograft bone but no difference in pain. Conclusions Patients with large or symptomatic lesions can be treated successfully with curettage and debridement, which leads to relief of pain. The use of bone grafting remains controversial.